In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, ...
read more ↘ molecular characterization, and genetic assays have led to many open questions and areas for which there is sparse or low-level evidence to support clinical decision-making.

The Advanced Prostate Cancer Consensus Conference (APCCC) was initiated to provide a forum to discuss and debate current questions on the clinical management of men with advanced prostate cancer, with a special focus on these unclear situations. Two days of the conference are dedicated to high-level presentations, discussions, and debates to summarize and conceptualize the available literature and evidence.

View our recent manuscript, Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), here: https://www.europeanurology.com/article/S0302-2838(24)02610-1/fulltext
↖ read less